Review





Similar Products

arca cap analog  (Jena Bioscience)
94
Jena Bioscience arca cap analog
Arca Cap Analog, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/arca cap analog/product/Jena Bioscience
Average 94 stars, based on 1 article reviews
arca cap analog - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
camptothecin analog payloads p1 p4  (MedChemExpress)
95
MedChemExpress camptothecin analog payloads p1 p4
Camptothecin Analog Payloads P1 P4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/camptothecin analog payloads p1 p4/product/MedChemExpress
Average 95 stars, based on 1 article reviews
camptothecin analog payloads p1 p4 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
anti reverse cap analog  (New England Biolabs)
95
New England Biolabs anti reverse cap analog
Anti Reverse Cap Analog, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti reverse cap analog/product/New England Biolabs
Average 95 stars, based on 1 article reviews
anti reverse cap analog - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
lucitanib  (MedChemExpress)
90
MedChemExpress lucitanib
In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, <t>lucitanib;</t> Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.
Lucitanib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lucitanib/product/MedChemExpress
Average 90 stars, based on 1 article reviews
lucitanib - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
fluorescent cholesterol analog  (MedChemExpress)
95
MedChemExpress fluorescent cholesterol analog
In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, <t>lucitanib;</t> Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.
Fluorescent Cholesterol Analog, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fluorescent cholesterol analog/product/MedChemExpress
Average 95 stars, based on 1 article reviews
fluorescent cholesterol analog - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
m7gp3g  (Jena Bioscience)
92
Jena Bioscience m7gp3g
In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, <t>lucitanib;</t> Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.
M7gp3g, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/m7gp3g/product/Jena Bioscience
Average 92 stars, based on 1 article reviews
m7gp3g - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier
analog vortex mixer  (Fisher Scientific)
86
Fisher Scientific analog vortex mixer
In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, <t>lucitanib;</t> Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.
Analog Vortex Mixer, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/analog vortex mixer/product/Fisher Scientific
Average 86 stars, based on 1 article reviews
analog vortex mixer - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
rapamycin analog  (TaKaRa)
96
TaKaRa rapamycin analog
In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, <t>lucitanib;</t> Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.
Rapamycin Analog, supplied by TaKaRa, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rapamycin analog/product/TaKaRa
Average 96 stars, based on 1 article reviews
rapamycin analog - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
thymidine analog  (Toronto Research Chemicals)
94
Toronto Research Chemicals thymidine analog
In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, <t>lucitanib;</t> Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.
Thymidine Analog, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/thymidine analog/product/Toronto Research Chemicals
Average 94 stars, based on 1 article reviews
thymidine analog - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
phyre2: protein homology/analogy recognition engine 2 polyphen-2  (Biotechnology Information)
86
Biotechnology Information phyre2: protein homology/analogy recognition engine 2 polyphen-2
In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, <t>lucitanib;</t> Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.
Phyre2: Protein Homology/Analogy Recognition Engine 2 Polyphen 2, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phyre2: protein homology/analogy recognition engine 2 polyphen-2/product/Biotechnology Information
Average 86 stars, based on 1 article reviews
phyre2: protein homology/analogy recognition engine 2 polyphen-2 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, lucitanib; Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.

Journal: iScience

Article Title: Mechanism-based prediction of drug synergy via network controllability analysis of therapeutic pathways in intractable diseases

doi: 10.1016/j.isci.2026.115339

Figure Lengend Snippet: In vitro experimental validation of the complement-type doublets and triplets that were predicted via SYNERGIE for CRC (A) The top 18 predicted complement-type drug combinations for CRC using the SYNERGIE-ET. The horizontal axis represents the drug combinations, whereas the vertical axis corresponds to the five types of prediction scores (see ). Blue and green indicate the prediction scores for drug A and drug B, respectively, with the color intensity reflecting the magnitude of the scores. Details can be found in . (B–I) Comparison of the survival ratios of CRC cells among Asp, an antineoplastic drug, and their combination. Gray represents single drugs (singlets), and blue represents the combination (doublet). Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (J–O) Comparison of the survival ratios of CRC cells among PB, an antineoplastic drug, and their combination. These panels follow the same format as (B–I). (P) Heatmap of the dose-response synergy scores of Asp doublets. The vertical axis represents the doses of Asp, and the horizontal axis shows drugs predicted to be Asp partners. The color scale reflects the IA scores, with positive values indicating synergistic effects and negative values indicating nonsynergistic effects. Each box is annotated with the corresponding IA score. Data are presented as mean values from independent experiments. Standard deviation values are provided in the . (Q) Comparison of the dose-response survival ratios between Oxa, a first-line drug for CRC, alone (singlet) and the Oxa-Asp doublet. In the Oxa-Asp doublet, the dose of Asp was fixed at 1 mM while the dose of Oxa was varied. The horizontal and vertical axes represent the doses of Oxa (μM) and the mean survival ratios of CRC cells, respectively. Error bars represent standard deviations (SD). The gray and blue points correspond to Oxa and the Oxa-Asp combination, respectively. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. (R) Comparison of CRC cell survival ratios among singlets, doublets, and the triplet combination: Oxa, Asp, and Ibru. The horizontal axis represents the drugs, and the vertical axis represents the mean survival ratios. Error bars indicate SD. The color bar reflects the IA scores for each drug combination, with values indicating the IA scores. Disease abbreviations: CRC, colorectal cancer. Drug abbreviations: Asp, aspirin; Chl, chlorotrianisene; Ced, cediranib; Das, dasatinib; Ibru, ibrutinib; Inf, infigratinib; Luc, lucitanib; Mir, mirdametinib; Oxa, oxaliplatin; PB, sodium phenylbutyrate; Pim, pimasertib; Pon, ponatinib; Sar, saracatinib; Tac, tacedinaline; Tan, tanespimycin; and Van, vandetanib.

Article Snippet: Lucitanib , MedChemExpress , Cat# HY-18951.

Techniques: In Vitro, Biomarker Discovery, Comparison, Standard Deviation